Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells

@inproceedings{Mandl2011ImmunotherapyWM,
  title={Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells},
  author={Stefanie J. Mandl and Ryan B. Rountree and Katie Dalpozzo and Lisa Nguyen Quang Do and John R. Lombardo and Peter L. Schoonmaker and Ulrike Dirmeier and Robin Steigerwald and Thierry D. Giffon and Reiner San Carlos Laus and Alain Delcayre},
  booktitle={Cancer Immunology, Immunotherapy},
  year={2011}
}
MVA-BN®-HER2 is a new candidate immunotherapy designed for the treatment of HER-2-positive breast cancer. Here, we demonstrate that a single treatment with MVA-BN®-HER2 exerts potent anti-tumor efficacy in a murine model of experimental pulmonary metastasis. This anti-tumor efficacy occurred despite a strong tumor-mediated immunosuppressive environment characterized by a high frequency of regulatory T cells (Treg) in the lungs of tumor-bearing mice. Immunogenicity studies showed that treatment… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 16 CITATIONS

Similar Papers

Loading similar papers…